US 11446332
Combinatorial cancer immunotherapy
granted A61KA61K2239/31A61K2239/38
Quick answer
US patent 11446332 (Combinatorial cancer immunotherapy) held by Senti Biosciences, Inc. expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Senti Biosciences, Inc.
- Grant date
- Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K2239/31, A61K2239/38, A61K2239/49, A61K2239/50